Post Marketing Surveillance Study for ONIVYDE® in South Korea

CompletedOBSERVATIONAL
Enrollment

94

Participants

Timeline

Start Date

March 8, 2018

Primary Completion Date

August 29, 2020

Study Completion Date

August 29, 2020

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

ONIVYDE

irinotecan liposome injection

DRUG

5-fluorouracil

a nucleoside metabolic inhibitor

DRUG

Leucovorin

an active metabolite of folic acid

Trial Locations (10)

10408

National Cancer Center, Gyeonggi-do

16499

Ajou University Hospital, Suwon

35365

Konyang University Hospital, Daejeon

03722

Severance Hospital, Yonsei University Health System - Gastroenterology, Seoul

Severance Hospital, Yonsei University Health System - Oncology, Seoul

05505

ASAN Medical Center, Seoul

06273

Gangnam Severance Hospital, Yonsei University Health System, Seoul

06351

Samsung Medical Center - Oncology, Seoul

06591

The Catholic University of Korea Seoul St.Mary's Hospital, Seoul

08308

Korea University Guro Hospital, Seoul

All Listed Sponsors
collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER

NCT03446872 - Post Marketing Surveillance Study for ONIVYDE® in South Korea | Biotech Hunter | Biotech Hunter